EcoDrugPlus

Advanced Glycosylation End-Product Specific Receptor

Ensembl ID : ENSTSYG00000005684
Gene Symbol: AGER
3 Cross references
169 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alcohol Dehydrogenase Class-3

Ensembl ID : ENSTSYG00000000589
Gene Symbol: LOC103270912
2 Cross references
399 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alcohol Dehydrogenase Class-3-Like

Ensembl ID : ENSTSYG00000002076
Gene Symbol: LOC103272380
2 Cross references
399 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSTSYG00000025900
Gene Symbol: AKR1B1
3 Cross references
429 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alpha Glucosidase

Ensembl ID : ENSTSYG00000003300
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amiloride-Sensitive Sodium Channel Subunit Alpha

Ensembl ID : ENSTSYG00000032098
Gene Symbol: LOC103250567
2 Cross references
153 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amine Oxidase Copper Containing 1

Ensembl ID : ENSTSYG00000036481
Gene Symbol: AOC1
3 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amine Oxidase Copper Containing 3

Ensembl ID : ENSTSYG00000031390
Gene Symbol: AOC3
3 Cross references
321 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amyloid P Component, Serum

Ensembl ID : ENSTSYG00000013052
Gene Symbol: APCS
3 Cross references
440 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amyloid Beta Precursor Protein

Ensembl ID : ENSTSYG00000010922
Gene Symbol: APP
3 Cross references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Androgen Receptor

Ensembl ID : ENSTSYG00000009965
Gene Symbol: AR
3 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSTSYG00000013739
Gene Symbol: AGTR1
1 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).